Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

The patient was diagnosed as Acute Myeloid Leukemia (AML) M 1 (according to French–American–British classification ... Thorough search of literature revealed that the first case of circulating MMGK ...

A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...

A four-year, $1.2 million grant from the National Cancer Institute of the National Institutes of Health may help researchers ...

ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination ...

A four-year, $1.2 million grant ... cytarabine against myeloid leukemia associated with DS. Children with DS are known to have a significantly higher risk of developing acute leukemias compared ...

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today ...

and to CB-012 for relapsed or refractory acute myeloid leukemia (r/r AML). CB-010, an allogeneic anti-CD19 CAR-T cell therapy, will be evaluated in the GALLOP Phase 1 clinical trial in patients ...